MIRA PHARMACEUTICALS INC (MIRA) Stock Price & Overview

NASDAQ:MIRA • US60458C1045

Current stock price

1.02 USD
-0.03 (-2.86%)
At close:
1.03 USD
+0.01 (+0.98%)
After Hours:

The current stock price of MIRA is 1.02 USD. Today MIRA is down by -2.86%. In the past month the price decreased by -0.97%. In the past year, price decreased by -12.07%.

MIRA Key Statistics

52-Week Range0.9 - 2.45
Current MIRA stock price positioned within its 52-week range.
1-Month Range0.9633 - 1.14
Current MIRA stock price positioned within its 1-month range.
Market Cap
42.86M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-1.52
Dividend Yield
N/A

MIRA Stock Performance

Today
-2.86%
1 Week
-8.93%
1 Month
-0.97%
3 Months
-17.74%
Longer-term
6 Months -38.92%
1 Year -12.07%
2 Years +20.01%
3 Years N/A
5 Years N/A
10 Years N/A

MIRA Stock Chart

MIRA PHARMACEUTICALS INC / MIRA Daily stock chart

MIRA Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to MIRA. When comparing the yearly performance of all stocks, MIRA is a bad performer in the overall market: 83.69% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

MIRA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to MIRA. MIRA has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

MIRA Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateMar 31, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

MIRA Forecast & Estimates

7 analysts have analysed MIRA and the average price target is 3.06 USD. This implies a price increase of 200% is expected in the next year compared to the current price of 1.02.


Analysts
Analysts82.86
Price Target3.06 (200%)
EPS Next Y84.62%
Revenue Next YearN/A

MIRA Groups

Sector & Classification

Sub-Industry
Pharmaceuticals
Index Membership

MIRA Financial Highlights

Over the last trailing twelve months MIRA reported a non-GAAP Earnings per Share(EPS) of -1.52. The EPS decreased by -215.64% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-32.00M
Industry RankSector Rank
PM (TTM) N/A
ROA -288.45%
ROE -307.94%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1.17%
Sales Q2Q%N/A
EPS 1Y (TTM)-215.64%
Revenue 1Y (TTM)N/A

MIRA Ownership

Ownership
Inst Owners5.94%
Shares42.02M
Float34.81M
Ins Owners11.11%
Short Float %1.26%
Short Ratio2.8

About MIRA

Company Profile

MIRA logo image MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

Company Info

IPO: 2023-08-03

MIRA PHARMACEUTICALS INC

1200 Brickell Avenue, Suite 1950 #1183

Miami FLORIDA US

Employees: 3

MIRA Company Website

MIRA Investor Relations

Phone: 18133695150

MIRA PHARMACEUTICALS INC / MIRA FAQ

What does MIRA PHARMACEUTICALS INC do?

MIRA Pharmaceuticals, Inc. operates as a clinical development stage biopharmaceutical company. The company is headquartered in Miami, Florida. The company went IPO on 2023-08-03. The firm is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The firm's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. The company holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.


What is the stock price of MIRA PHARMACEUTICALS INC today?

The current stock price of MIRA is 1.02 USD. The price decreased by -2.86% in the last trading session.


Does MIRA PHARMACEUTICALS INC pay dividends?

MIRA does not pay a dividend.


How is the ChartMill rating for MIRA PHARMACEUTICALS INC?

MIRA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


What sector and industry does MIRA PHARMACEUTICALS INC belong to?

MIRA PHARMACEUTICALS INC (MIRA) operates in the Health Care sector and the Pharmaceuticals industry.


Can you provide the upcoming earnings date for MIRA PHARMACEUTICALS INC?

MIRA PHARMACEUTICALS INC (MIRA) will report earnings on 2026-05-12.